Prosecution Insights
Last updated: April 19, 2026

Examiner: HARTLEY, MICHAEL G

Tech Center 1600 • Art Units: 1600 1611 1618

This examiner grants 33% of resolved cases

Performance Statistics

33.3%
Allow Rate
-26.7% vs TC avg
75
Total Applications
+78.2%
Interview Lift
1788
Avg Prosecution Days
Based on 63 resolved cases, 2023–2026

Rejection Statute Breakdown

2.5%
§101 Eligibility
20.3%
§102 Novelty
41.4%
§103 Obviousness
21.7%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
17365733 DESIGN AND DEVELOPMENT OF NEUROKININ-1 RECEPTOR-BINDING AGENT DELIVERY CONJUGATES Final Rejection Purdue Research Foundation
17539442 METHODS AND COMPOSITIONS FOR 18F-RADIOLABELING OF BIOLOGICS Final Rejection BRISTOL-MYERS SQUIBB COMPANY
17712479 PLASMONICS-ACTIVE METAL NANOSTAR COMPOSITIONS AND METHODS OF USE Non-Final OA Duke University
17294375 MACROCYCLIC COMPLEXES OF RADIONUCLIDES AND THEIR USE IN RADIOTHERAPY OF CANCER Non-Final OA Cornell University
17053691 MAGNETIC LIPOSOMES AND RELATED TREATMENT AND IMAGING METHODS Non-Final OA UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED
16964733 CONJUGATABLE DESMOGLEIN 2 (DSG2) BINDING PROTEINS AND USES THEREFOR Final Rejection HDT BIO CORP.
17264944 POLYPEPTIDE DELIVERY COMPOSITION Non-Final OA LEMONEX INC.
18109031 Benzylideneaminoguanidine derivatives as NR2B-selective NMDA receptor antagonists and their therapeutic applications Final Rejection InFlectis BioScience
17914061 INHALED XENON THERAPY IN NEURODEGENERATIVE DISEASE Final Rejection General Biophysics LLC
17484727 Enhanced in Vivo Targeting of Site-Specific Drugs Non-Final OA Advanced Accelerator Applications USA, Inc.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month